文献速递腹部MR

非增强MRI肝表面结节度识别NAFLD晚期纤维化

Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD.
PubMed 文献 · Eur Radiol · 2021-09-17

本研究回顾性分析142例病理证实的NAFLD患者,评估非增强MRI肝表面结节度(LSN)对晚期纤维化(F3-F4)的诊断效能。结果显示MRI-LSN≥2.50的AUC为0.838(95%CI 0.767-0.894),敏感度67.3%、特异度88.9%,联合FIB-4可正确分类73%患者,并在75例外部队列中验证。

要点

  • MRI-LSN≥2.50诊断NAFLD晚期纤维化AUC 0.838,特异度88.9%。
  • 联合FIB-4与MRI-LSN可提高晚期纤维化检出,正确分类73%患者。
  • LSN可从常规非增强MRI序列获得,无需额外对比剂。

关键影像表现/征象

  • MRI-PDFF中位数随脂肪变性分级S1、S2、S3分别增至8.1%、18.1%、31%(p < 0.001)。
  • 肝表面结节度(LSN)在非增强MR序列上评估,用于反映晚期纤维化。

诊断标准与关键数值

  • MRI-LSN≥2.50诊断晚期纤维化(F3-F4)的AUC为0.838(95%CI 0.767-0.894),敏感度67.3%,特异度88.9%,阳性预测值77.8%,阴性预测值82.5%。
  • 联合FIB-4与MRI-LSN正确分类103/142(73%)患者。

临床应用与阅片要点

  • 可利用常规非增强MRI序列测量LSN,无需增强扫描。
  • LSN≥2.50提示晚期纤维化可能,建议结合FIB-4综合评估。

局限性

  • 回顾性研究设计。
  • 单中心来源为主,外部队列样本量75例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic performance of liver surface nodularity (LSN) for the assessment of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).

METHODS: We retrospectively analysed patients with pathologically proven NAFLD who underwent liver MRI. Demographic, clinical, and laboratory data (including FIB-4 scores) were gathered. The SAF score was used to assess NAFLD. MRI-proton density fat fraction (PDFF) and LSN were determined on pre-contrast MR sequences. ROC curve analysis was performed to evaluate the diagnostic performance of MRI-LSN for the diagnosis of advanced (F3-F4) liver fibrosis.

RESULTS: The final population included 142 patients. Sixty-seven (47%) patients had non-alcoholic steatohepatitis (NASH), and 52 (37%) had advanced fibrosis. The median MRI-PDFF increased with the grades of steatosis: 8.1%, 18.1%, and 31% in S1, S2, and S3 patients, respectively (p < 0.001). The area under the ROC curve (AUC) of MRI-LSN ≥ 2.50 was 0.838 (95%CI 0.767-0.894, sensitivity 67.3%, specificity 88.9%, positive and negative predictive values 77.8% and 82.5%, respectively) for the diagnosis of advanced fibrosis. Combining FIB-4 and MRI-LSN correctly classified 103/142 (73%) patients. This was validated in an external cohort of 75 patients.

CONCLUSIONS: MRI-LSN has good diagnostic performance in diagnosis of advanced fibrosis in NAFLD patients. A combination of FIB-4 and MRI-LSN derived from pre-contrast MRI could be helpful to detect advanced fibrosis.

KEY POINTS: • MRI-LSN ≥ 2.5 was accurate for the diagnosis of advanced hepatic fibrosis in NAFLD patients. • The combination of FIB-4 and MRI-LSN improved the detection of advanced fibrosis. • MRI-LSN can be easily derived by unenhanced MRI sequences that are routinely acquired.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Dioguardi Burgio M, Sartoris R, Beaufrere A, et al. Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. Eur Radiol. 2021. PMID: 34533606. doi:10.1007/s00330-021-08261-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。